Pluristem Therapeutics (PSTI) was Resumed by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $3.50. H.C. Wainwright advised their investors in a research report released on Jul 19, 2016.
Pluristem Therapeutics opened for trading at $1.46 and hit $1.48 on the upside on Monday, eventually ending the session at $1.479, with a gain of 2.36% or 0.0341 points. The heightened volatility saw the trading volume jump to 94,460 shares. Company has a market cap of $119 M.
In a different news, on Jun 6, 2016, Doron Shorrer (director) sold 12,346 shares at $1.52 per share price. According to the SEC, on Feb 24, 2016, Zami Aberman (CEO) purchased 5,000 shares at $1.33 per share price. On Feb 22, 2016, Yaky Yanay (CFO) purchased 5,000 shares at $1.20 per share price, according to the Form-4 filing with the securities and exchange commission.
Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions. The Company focuses on cardiovascular orthopedic pulmonary hematological and women’s health diseases. The Company is focused on the research development clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s placenta expanded (PLX) cells are intended to function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals that are generated by the patient’s own body. PLX cells are grown using its three-dimensional (3D) micro environment technology which produces a product that requires no tissue matching prior to administration. Its PLX products are in clinical-stage development for multiple indications.